CA3034262A1 - A crystalline 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid - Google Patents
A crystalline 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid Download PDFInfo
- Publication number
- CA3034262A1 CA3034262A1 CA3034262A CA3034262A CA3034262A1 CA 3034262 A1 CA3034262 A1 CA 3034262A1 CA 3034262 A CA3034262 A CA 3034262A CA 3034262 A CA3034262 A CA 3034262A CA 3034262 A1 CA3034262 A1 CA 3034262A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- crystalline compound
- disorder
- xrpd pattern
- crystalline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378582P | 2016-08-23 | 2016-08-23 | |
| US62/378,582 | 2016-08-23 | ||
| PCT/US2017/048267 WO2018039378A1 (en) | 2016-08-23 | 2017-08-23 | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3034262A1 true CA3034262A1 (en) | 2018-03-01 |
Family
ID=59772778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3034262A Pending CA3034262A1 (en) | 2016-08-23 | 2017-08-23 | A crystalline 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US11236121B2 (enExample) |
| EP (2) | EP3504189A1 (enExample) |
| JP (3) | JP2019524853A (enExample) |
| KR (2) | KR20230079470A (enExample) |
| CN (4) | CN115974954A (enExample) |
| AR (3) | AR109393A1 (enExample) |
| AU (3) | AU2017315682B2 (enExample) |
| BR (1) | BR112019003637A2 (enExample) |
| CA (1) | CA3034262A1 (enExample) |
| CL (2) | CL2019000477A1 (enExample) |
| CO (1) | CO2019002596A2 (enExample) |
| EA (1) | EA201990565A1 (enExample) |
| EC (1) | ECSP19020141A (enExample) |
| IL (2) | IL302480A (enExample) |
| JO (1) | JOP20190022B1 (enExample) |
| MA (1) | MA46042A (enExample) |
| MX (2) | MX393240B (enExample) |
| MY (1) | MY200479A (enExample) |
| NZ (1) | NZ791594A (enExample) |
| PE (2) | PE20241580A1 (enExample) |
| PH (1) | PH12019500375A1 (enExample) |
| SG (1) | SG11201901445TA (enExample) |
| TW (2) | TWI854445B (enExample) |
| WO (1) | WO2018039378A1 (enExample) |
| ZA (1) | ZA201901051B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104136452A (zh) | 2011-10-14 | 2014-11-05 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| SI2986624T1 (sl) | 2013-04-17 | 2020-10-30 | Sage Therapeutics, Inc. | 19-nor nevroaktivni steroidi za metode zdravljenja |
| EP2986623B1 (en) | 2013-04-17 | 2018-11-07 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| SI3021852T1 (sl) | 2013-07-19 | 2021-07-30 | Sage Therapeutics, Inc. | Nevroaktivni steroidi, sestavki in uporabe le-teh |
| JP6466942B2 (ja) | 2013-08-23 | 2019-02-06 | セージ セラピューティクス， インコーポレイテッド | 向神経活性ステロイド、組成物、及びその使用 |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| RS60642B1 (sr) | 2014-10-16 | 2020-09-30 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns-a |
| EP4527461A3 (en) | 2014-10-16 | 2025-06-25 | Sage Therapeutics, Inc. | A compound, compositions thereof and this compound for use in methods of treating cns disorders |
| SMT202000276T1 (it) | 2014-11-27 | 2020-07-08 | Sage Therapeutics Inc | Composizioni e metodi per trattare disturbi del snc |
| SMT202100113T1 (it) | 2015-01-26 | 2021-05-07 | Sage Therapeutics Inc | Composizioni e metodi per trattare disturbi del snc |
| JP6875996B2 (ja) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
| IL264129B2 (en) | 2016-07-11 | 2024-05-01 | Sage Therapeutics Inc | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| NZ790187A (en) | 2016-07-11 | 2025-08-29 | Sage Therapeutics Inc | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| TWI854445B (zh) | 2016-08-23 | 2024-09-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| AU2018327357B2 (en) * | 2017-09-07 | 2024-08-22 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| US20220110949A1 (en) * | 2017-09-14 | 2022-04-14 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| WO2019113494A1 (en) | 2017-12-08 | 2019-06-13 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| EP3806863A1 (en) * | 2018-06-12 | 2021-04-21 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| IL312610A (en) | 2018-12-05 | 2024-07-01 | Sage Therapeutics Inc | Neuroactive steroids and methods of using them |
| CN111454318A (zh) | 2019-01-20 | 2020-07-28 | 浙江易众化工有限公司 | 抗抑郁药物sage-217的晶型及其制备方法 |
| WO2020155057A1 (zh) * | 2019-01-31 | 2020-08-06 | 深圳仁泰医药科技有限公司 | γ-氨基丁酸调节剂的晶型X及其制备方法和应用 |
| WO2020242772A1 (en) | 2019-05-28 | 2020-12-03 | Teva Czech Industries S.R.O | Solid state forms of sage-217 and processes for preparation thereof |
| SG11202112391UA (en) | 2019-05-31 | 2021-12-30 | Sage Therapeutics Inc | Neuroactive steroids and compositions thereof |
| JP7726867B6 (ja) * | 2019-08-07 | 2025-09-18 | 上▲海▼翰森生物医▲薬▼科技有限公司 | ステロイド誘導体調節因子の塩及び結晶形態 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| PE20221911A1 (es) | 2020-03-25 | 2022-12-23 | Sage Therapeutics Inc | Uso de agentes para el tratamiento de condiciones respiratorias |
| EP4181884A1 (en) * | 2020-07-20 | 2023-05-24 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| EP4199723A4 (en) * | 2020-10-01 | 2024-09-04 | Eliem Therapeutics (UK) Ltd | METHODS OF TREATMENT OF FIBROMYALGIA WITH NEUROACTIVE STEROIDS |
| IL304080A (en) | 2021-01-28 | 2023-08-01 | Sage Therapeutics Inc | Use of neuroactive steroids for treatment of sexual dysfunction |
| EP4308162A1 (en) | 2021-03-17 | 2024-01-24 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
| MX2023012727A (es) | 2021-04-29 | 2023-11-08 | Sage Therapeutics Inc | Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto. |
| MX2023012728A (es) | 2021-04-29 | 2023-11-08 | Sage Therapeutics Inc | Esteroide neuroactivo para el tratamiento del trastorno depresivo mayor y la depresion posparto en una mujer lactante. |
| MX2024001372A (es) | 2021-07-28 | 2024-02-27 | Sage Therapeutics Inc | Formas cristalinas de un esteroide neuroactivo. |
| CA3252357A1 (en) | 2022-02-16 | 2023-08-24 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS FOR THE TREATMENT OF CNS DISORDERS |
| US20250177418A1 (en) | 2022-02-28 | 2025-06-05 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| SK9742002A3 (en) | 2000-01-07 | 2003-02-04 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| TWI305530B (en) | 2002-02-08 | 2009-01-21 | Ono Pharmaceutical Co | Piperidine derivative compound and pharmaceuticals containing same as active ingredient |
| WO2011079047A1 (en) | 2009-12-23 | 2011-06-30 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| EP2736919A4 (en) | 2011-07-29 | 2015-01-14 | Univ California | NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
| WO2013043985A1 (en) | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| CN104136452A (zh) | 2011-10-14 | 2014-11-05 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| DK2806877T3 (da) | 2012-01-23 | 2019-11-04 | Sage Therapeutics Inc | Neuroaktive steroidformuleringer omfattende et kompleks af allopregnanolon og sulfobutylether beta-cyclodekstrin |
| US20150175651A1 (en) | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| WO2014058736A1 (en) | 2012-10-08 | 2014-04-17 | Washington University | Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| JP2016501876A (ja) | 2012-11-30 | 2016-01-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ステロイドの抗痙攣活性 |
| RS57390B1 (sr) | 2012-12-18 | 2018-09-28 | Univ Washington | Neuroaktivni 19-alkoksi-17-supstituisani steroidi, primenjivi u postupcima lečenja |
| SI2986624T1 (sl) | 2013-04-17 | 2020-10-30 | Sage Therapeutics, Inc. | 19-nor nevroaktivni steroidi za metode zdravljenja |
| EP2986623B1 (en) | 2013-04-17 | 2018-11-07 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| SI3021852T1 (sl) | 2013-07-19 | 2021-07-30 | Sage Therapeutics, Inc. | Nevroaktivni steroidi, sestavki in uporabe le-teh |
| JP6466942B2 (ja) | 2013-08-23 | 2019-02-06 | セージ セラピューティクス， インコーポレイテッド | 向神経活性ステロイド、組成物、及びその使用 |
| TWI839649B (zh) | 2014-05-29 | 2024-04-21 | 美商賽吉醫療公司 | 神經活性類固醇，其組合物及其用途 |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| RS60642B1 (sr) * | 2014-10-16 | 2020-09-30 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns-a |
| EP4527461A3 (en) | 2014-10-16 | 2025-06-25 | Sage Therapeutics, Inc. | A compound, compositions thereof and this compound for use in methods of treating cns disorders |
| SMT202000276T1 (it) | 2014-11-27 | 2020-07-08 | Sage Therapeutics Inc | Composizioni e metodi per trattare disturbi del snc |
| SMT202100113T1 (it) | 2015-01-26 | 2021-05-07 | Sage Therapeutics Inc | Composizioni e metodi per trattare disturbi del snc |
| JP6875996B2 (ja) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
| WO2016164763A1 (en) | 2015-04-10 | 2016-10-13 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MA45276A (fr) | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| JP2018526423A (ja) | 2015-09-08 | 2018-09-13 | ビューポイント セラピューティクス， インコーポレイテッド | 眼科疾患を処置するための化合物および製剤 |
| MX2018004376A (es) | 2015-10-16 | 2018-08-01 | Marinus Pharmaceuticals Inc | Formulaciones inyectables de neuroesteroides que contienen nanoparticulas. |
| US20200306262A1 (en) | 2015-11-20 | 2020-10-01 | Sage Therapeutics, Inc. | Compounds and methods of their use |
| WO2017156103A1 (en) | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| IL264129B2 (en) | 2016-07-11 | 2024-05-01 | Sage Therapeutics Inc | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| NZ790187A (en) | 2016-07-11 | 2025-08-29 | Sage Therapeutics Inc | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| TWI854445B (zh) | 2016-08-23 | 2024-09-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
| WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
| CN111065394B (zh) | 2017-08-31 | 2023-03-31 | 武田药品工业株式会社 | 中枢神经系统病症的治疗 |
| AU2018327357B2 (en) | 2017-09-07 | 2024-08-22 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| WO2019051477A1 (en) | 2017-09-11 | 2019-03-14 | Sage Therapeutics, Inc. | METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION |
| US20220110949A1 (en) | 2017-09-14 | 2022-04-14 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| SG10202110563YA (en) | 2017-11-10 | 2021-11-29 | Marinus Pharmaceuticals Inc | Ganaxolone for use in treating genetic epileptic disoders |
| WO2019113494A1 (en) | 2017-12-08 | 2019-06-13 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| MA51315A (fr) | 2017-12-22 | 2020-10-28 | Sage Therapeutics Inc | Compositions et méthodes permettant de traiter des troubles du snc |
| EP3728285A1 (en) | 2017-12-22 | 2020-10-28 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MA51568A (fr) | 2018-01-12 | 2021-04-21 | Sage Therapeutics Inc | Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central |
| EP3806863A1 (en) | 2018-06-12 | 2021-04-21 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| BR112021009428A2 (pt) | 2018-10-12 | 2021-08-31 | Sage Therapeutics, Inc. | Esteroides neuroativos substituídos na posição 10 por um grupo cíclico para uso no tratamento de distúrbios do cns |
| CA3116892A1 (en) | 2018-10-19 | 2020-04-23 | Sage Therapeutics, Inc. | 9(11)-unsaturated neuroactive steroids and their methods of use |
| IL312610A (en) | 2018-12-05 | 2024-07-01 | Sage Therapeutics Inc | Neuroactive steroids and methods of using them |
| AU2019403415B2 (en) | 2018-12-21 | 2025-08-21 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof |
| TW202523658A (zh) | 2019-05-24 | 2025-06-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| SG11202112391UA (en) | 2019-05-31 | 2021-12-30 | Sage Therapeutics Inc | Neuroactive steroids and compositions thereof |
| CN114729000A (zh) | 2019-06-27 | 2022-07-08 | 萨奇治疗股份有限公司 | 用于治疗cns病症的化合物 |
| BR112021026447A2 (pt) | 2019-06-27 | 2022-04-12 | Sage Therapeutics Inc | Composições e métodos para tratamento de distúrbios de cns |
| CA3143509A1 (en) | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| IL293510A (en) | 2019-12-05 | 2022-08-01 | Sage Therapeutics Inc | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| CN115551874A (zh) | 2020-03-18 | 2022-12-30 | 萨奇治疗股份有限公司 | 神经活性类固醇及其使用方法 |
| PE20221911A1 (es) | 2020-03-25 | 2022-12-23 | Sage Therapeutics Inc | Uso de agentes para el tratamiento de condiciones respiratorias |
| EP4172171A1 (en) | 2020-06-24 | 2023-05-03 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof |
| EP4181884A1 (en) | 2020-07-20 | 2023-05-24 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| IL303101A (en) | 2020-11-25 | 2023-07-01 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| IL304080A (en) | 2021-01-28 | 2023-08-01 | Sage Therapeutics Inc | Use of neuroactive steroids for treatment of sexual dysfunction |
| US20240148756A1 (en) | 2021-02-18 | 2024-05-09 | Sage Therapeutics, Inc. | Use of neuroactive steroid for treatment of sexual dysfunction |
| EP4308162A1 (en) | 2021-03-17 | 2024-01-24 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
| EP4322960A1 (en) | 2021-04-12 | 2024-02-21 | Sage Therapeutics, Inc. | Treatment of essential tremor |
| MX2023012728A (es) | 2021-04-29 | 2023-11-08 | Sage Therapeutics Inc | Esteroide neuroactivo para el tratamiento del trastorno depresivo mayor y la depresion posparto en una mujer lactante. |
| MX2023012727A (es) | 2021-04-29 | 2023-11-08 | Sage Therapeutics Inc | Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto. |
| CA3252357A1 (en) | 2022-02-16 | 2023-08-24 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS FOR THE TREATMENT OF CNS DISORDERS |
| US20250177418A1 (en) | 2022-02-28 | 2025-06-05 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
-
2017
- 2017-08-23 TW TW112101437A patent/TWI854445B/zh active
- 2017-08-23 TW TW106128611A patent/TWI808945B/zh active
- 2017-08-23 IL IL302480A patent/IL302480A/en unknown
- 2017-08-23 NZ NZ791594A patent/NZ791594A/en unknown
- 2017-08-23 US US16/326,977 patent/US11236121B2/en active Active
- 2017-08-23 MY MYPI2019000844A patent/MY200479A/en unknown
- 2017-08-23 PE PE2024000634A patent/PE20241580A1/es unknown
- 2017-08-23 EA EA201990565A patent/EA201990565A1/ru unknown
- 2017-08-23 MX MX2019002193A patent/MX393240B/es unknown
- 2017-08-23 CN CN202210890024.3A patent/CN115974954A/zh active Pending
- 2017-08-23 AR ARP170102330A patent/AR109393A1/es not_active Application Discontinuation
- 2017-08-23 KR KR1020237017309A patent/KR20230079470A/ko active Pending
- 2017-08-23 SG SG11201901445TA patent/SG11201901445TA/en unknown
- 2017-08-23 CN CN201780063826.4A patent/CN110088091A/zh active Pending
- 2017-08-23 CN CN202210890054.4A patent/CN115974956A/zh active Pending
- 2017-08-23 BR BR112019003637A patent/BR112019003637A2/pt not_active Application Discontinuation
- 2017-08-23 JP JP2019510657A patent/JP2019524853A/ja not_active Withdrawn
- 2017-08-23 EP EP17761714.9A patent/EP3504189A1/en not_active Withdrawn
- 2017-08-23 KR KR1020197008069A patent/KR20190040043A/ko not_active Ceased
- 2017-08-23 CN CN202210890025.8A patent/CN115974955A/zh active Pending
- 2017-08-23 AU AU2017315682A patent/AU2017315682B2/en active Active
- 2017-08-23 PE PE2019000416A patent/PE20190915A1/es unknown
- 2017-08-23 EP EP21190443.8A patent/EP3981763A1/en active Pending
- 2017-08-23 WO PCT/US2017/048267 patent/WO2018039378A1/en not_active Ceased
- 2017-08-23 IL IL315950A patent/IL315950A/en unknown
- 2017-08-23 JO JOP/2019/0022A patent/JOP20190022B1/ar active
- 2017-08-23 CA CA3034262A patent/CA3034262A1/en active Pending
- 2017-08-23 MA MA046042A patent/MA46042A/fr unknown
-
2019
- 2019-02-19 ZA ZA2019/01051A patent/ZA201901051B/en unknown
- 2019-02-21 PH PH12019500375A patent/PH12019500375A1/en unknown
- 2019-02-22 CL CL2019000477A patent/CL2019000477A1/es unknown
- 2019-02-22 MX MX2022007432A patent/MX2022007432A/es unknown
- 2019-03-20 CO CONC2019/0002596A patent/CO2019002596A2/es unknown
- 2019-03-22 EC ECSENADI201920141A patent/ECSP19020141A/es unknown
- 2019-12-10 CL CL2019003610A patent/CL2019003610A1/es unknown
-
2021
- 2021-08-06 US US17/396,464 patent/US11884696B2/en active Active
-
2022
- 2022-02-08 AU AU2022200811A patent/AU2022200811B9/en active Active
- 2022-04-08 AR ARP220100894A patent/AR125320A2/es unknown
- 2022-04-08 AR ARP220100895A patent/AR125321A2/es unknown
- 2022-11-07 JP JP2022178009A patent/JP2023002846A/ja active Pending
-
2023
- 2023-08-24 US US18/455,324 patent/US12358942B2/en active Active
-
2024
- 2024-02-06 AU AU2024200732A patent/AU2024200732A1/en active Pending
- 2024-05-07 JP JP2024075299A patent/JP2024097878A/ja active Pending
-
2025
- 2025-06-11 US US19/234,808 patent/US20250304615A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022200811B2 (en) | A crystalline 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroid | |
| WO2019051264A1 (en) | NEUROACTIVE STEROIDS AND METHODS OF USE | |
| EP4543899A1 (en) | Crystalline forms of a neuroactive steroid | |
| WO2024015201A1 (en) | Crystalline form of a neuroactive steroid | |
| HK40073101A (en) | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid | |
| OA19368A (en) | A crystalline 19-Nor C3, 3-disubstituted C21-N-Pyrazolyl steroid. | |
| EA044239B1 (ru) | Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид | |
| NZ791591A (en) | A crystalline 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroid | |
| BR122024016008A2 (pt) | Formas sólidas cristalinas de um composto esteróide | |
| BR122024016003A2 (pt) | Formas sólidas cristalinas de um composto esteróide, composição farmacêutica e composto cristalino | |
| TWI904593B (zh) | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 | |
| WO2024026337A1 (en) | Crystalline forms of a neuroactive steroid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220817 |
|
| EEER | Examination request |
Effective date: 20220817 |
|
| EEER | Examination request |
Effective date: 20220817 |
|
| EEER | Examination request |
Effective date: 20220817 |
|
| EEER | Examination request |
Effective date: 20220817 |